Welcome to our dedicated page for Hookipa Pharma SEC filings (Ticker: HOOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The HOOKIPA Pharma Inc. (HOOK) SEC filings page on Stock Titan aggregates the company’s U.S. regulatory documents, offering a structured view of key events in its history as a listed clinical-stage biopharmaceutical company. HOOKIPA’s filings trace the evolution of a business focused on next generation immunotherapeutics based on a proprietary arenavirus platform, with programs in oncology and serious infectious diseases, including collaborations with Gilead Sciences, Inc. for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
For this issuer, several filing types are particularly important. Current reports on Form 8-K capture material events, such as the July 29, 2025 filing that discloses the results of a special meeting of stockholders. In that 8-K, HOOKIPA reports stockholder approval of the sale of certain assets to Gilead under an asset purchase agreement, approval of the liquidation and dissolution of the company and the related plan of dissolution, and approval of a proposal to permit adjournments of the special meeting if necessary. This filing provides formal confirmation of the company’s transition toward winding up.
Filings related to trading status and reporting obligations are also central for HOOKIPA. On July 29, 2025, the company filed a Form 25 to remove its common stock from listing and registration on the Nasdaq Capital Market, relying on the rule provision for voluntary withdrawal of a class of securities from listing and registration. On August 8, 2025, HOOKIPA filed a Form 15 to terminate the registration of its common stock under Section 12(g) of the Securities Exchange Act of 1934 and to suspend its duty to file reports under Sections 13 and 15(d). The Form 15 identifies the rule provisions relied upon and discloses the approximate number of holders of record at the certification date.
Earlier periodic reports such as Forms 10-K and 10-Q (referenced in the company’s press releases) provide broader context on HOOKIPA’s clinical-stage pipeline, collaboration arrangements, and risk factors, while Forms 3, 4 and 5 referenced in the company’s disclosures document insider holdings and transactions over time. On Stock Titan, these filings are updated from the SEC’s EDGAR system and are paired with AI-powered summaries that explain the significance of documents such as 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and specialized forms like Form 25 and Form 15. This helps readers quickly understand how HOOKIPA’s filings reflect its shift from an actively reporting Nasdaq-listed issuer to a company that has completed an asset sale, obtained approval for dissolution, delisted its shares, and moved to suspend its Exchange Act reporting obligations.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) has called a virtual special meeting for 10:00 a.m. ET on July 29, 2025 to seek shareholder approval for three critical proposals:
- Asset Sale (Proposal 1): Sale of all assets related to the HB-400 (Hepatitis B) and HB-500 (HIV) programs, including IP and know-how, to long-time collaborator and 5%+ shareholder Gilead Sciences for up to $10 million cash ( $3 million at closing plus up to $7 million in three post-closing transfer-plan tranches).
- Dissolution (Proposal 2): Liquidation of the company pursuant to a Plan of Dissolution, conditional upon successful closing of the Asset Sale.
- Adjournment (Proposal 3): Authority to adjourn the meeting if additional proxy solicitation is required.
The Board unanimously recommends voting “FOR” all proposals.
Key financial terms
- Estimated net proceeds from the transaction: $7.6 million after taxes and expenses, assuming full $10 million consideration is earned.
- Board projects liquidating distributions of approximately $1.28 – $1.72 per common and Class A share (based on 12.2 million diluted shares) but no earlier than three years after filing the Certificate of Dissolution.
- If the Transfer Plan phases are disputed, related cash installments may be delayed or forfeited, and the company cannot file its dissolution certificate until all phases are accepted or waived.
- No appraisal or dissenters’ rights apply.
Strategic rationale
- Limited cash, no marketed products, rising public-company costs and historically low trading liquidity led the Board to pursue a sale after a year-long strategic review that included but ultimately rejected an alternative transaction with Poolbeg Pharma.
- Transaction allows monetisation of non-core infectious-disease programs while providing shareholders an exit path.
Process & governance
- Majority of outstanding common shares (≈4.9 million) must vote “FOR” to pass Proposals 1 and 2.
- Executive officers and directors will receive accelerated vesting of 178,570 RSUs and 13,264 options upon closing.
- Failure to approve the Dissolution does not block the Asset Sale, but would leave HOOK with no active programs or clear strategy.
Timeline
- Closing targeted as soon as regulatory clearance (Austrian FDI filing) and shareholder approval obtained, but outside deadline is Nov 21 2025.
- Transfer books will close on the “Final Record Date” when the Certificate of Dissolution is filed; shares are expected to be delisted from Nasdaq shortly after the special meeting.